How Race and Financial Status Can Affect Access to CAR T-Cell Therapies Approved for Patients with B-cell Lymphoma

Chimeric antigen receptor T-cell (CAR-T) immunotherapy is an effective approved treatment for people with certain types of lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. However, recent studies have shown significant disparities in access and outcomes based on race and insurance status. This article delves into understanding these inequalities and their potential implications for patients.

Racial Disparities in CAR T-Cell Therapy

A study published recently examined the impact of race and insurance on CAR T-cell therapy outcomes for patients with lymphoma. While the study found no difference in treatment efficacy or toxicity based on race, it uncovered stark disparities in access to the clinical trial. Black patients were significantly underrepresented in the study population, suggesting potential barriers to referral or eligibility.

“In a real-world analysis of 1,389 patients receiving axicabtagene ciloleucel for DLBCL, 81% were White, 5% were AA, 6% were Asian, and 11% were Hispanic.”

Moreover, patients from lower socioeconomic backgrounds, often disproportionately represented by minority groups, were less likely to receive CAR T-cell therapy. These findings underscore the complex interplay between race, socioeconomic status, and access to advanced cancer treatments.

Insurance and Access to CAR T-Cell Therapy

The study explored the impact of insurance on access to CAR T-cell therapy. The study found that Medicare patients benefited the most from these therapies in terms of survival, although it could also be explained by a less aggressive disease in the studied group. Consistent with findings in other oncology studies, Medicaid patients had shorter survival when treated with CAR-T, which can be associated with more advanced or aggressive disease. 

The Role of Social Determinants of Health

The authors emphasized the importance of social determinants of health (SDOH) in shaping CAR T-cell therapy experiences. SDOH, such as income, education, and neighborhood environment, can significantly influence a patient's overall health and well-being. The study highlighted the need for a comprehensive approach to addressing cancer disparities, focusing not only on biological factors but also on the social context in which patients live.

“Disparities in outcomes for patients receiving CAR-T are likely just the tip of the iceberg and do not account for the many patients who are candidates for CAR-T but are either not referred or unable to be treated. Larger studies are needed to tease out the role of race vs. other social determinants of health, such as distance to the treatment center, income, and available social support, in CAR-T outcomes.”

Implications and Future Directions

Real-world studies underscore the urgent need to address racial and socioeconomic disparities in CAR T-cell therapy access and outcomes. While the reasons behind these disparities are complex and multifaceted, potential factors include differences in healthcare provider bias, insurance coverage, and patient education.

In order to tackle this problem, it will be necessary for patient advocacy groups, community oncology practices, national societies, and government organizations to collaborate. Researchers and healthcare providers need to work together to find and apply strategies that enhance the availability of CAR T-cell therapy for all patients. This may require focused outreach and educational initiatives, as well as policy adjustments to address insurance coverage and reimbursement obstacles.

Furthermore, additional research is necessary to elucidate the specific mechanisms underlying these disparities and to develop interventions tailored to the unique needs of underserved populations. By prioritizing equity and inclusivity, we can work towards a future where all patients have equal opportunities to benefit from the promise of CAR T-cell therapy.

People who are educated about their care live longer, better lives. At HealthTree, we are committed to providing the most accurate and up-to-date information about lymphoma. Whether you are looking for a specialist, need help interpreting test results, or want to learn about the latest treatments, we have what you need.

Explore HealthTree's Free Educational Resources

Sources: 

• Race and insurance: real-world insights on CAR-T outcomes
• Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
• Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma